Bayhill Therapeutics raises $35.4 million in Series B financing
News | 05. 04. 2005
Bayhill Therapeutics Inc. today announced the completion of a Series B private venture financing of $35.4 million led by De Novo Ventures and Lilly Ventures and joined by Series A shareholders, CMEA Ventures, Latterell Venture Partners, Morgenthaler Ventures, U.S. Venture Partners, and the Vertical Group. Participants in this new round of financing include A.M. Pappas Life Science Ventures; Boston Life Science Venture Corp (Taiwan); Grand Cathay Venture Capital Company, LTD (Taiwan); Montreux Equity Partners; PAC-LINK Bio Management Corp (Taiwan); Prudence Venture Investment Corp (Taiwan); and Quintiles’ PharmaBio Development.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.